Today, doctors are increasingly looking at the genetic makeup of each patient’s tumor to guide treatment decisions.

Braftovi plus Erbitux and FOLFIRI showed significant ORR benefits in BRAF V600E–mutant mCRC compared to the control regimen. The combination therapy achieved a confirmed ORR of 64.4% versus 39.2% with ...

A post hoc analysis of the PETACC-8 trial has revealed an interaction between microsatellite instability (MSI) and BRAF and KRAS mutation status when determining the prognosis of patients with ...

TAS-102 plus bevacizumab in refractory metastatic colorectal cancer: A systematic review and meta-analysis of randomized trials with validation from prospective single-arm studies. This is an ASCO ...

(RTTNews) - Guardant Health, Inc. (GH) said Thursday that the U.S. Food and Drug Administration has approved its Guardant360 CDx liquid biopsy test as a companion diagnostic for patients with BRAF ...

A review article led by researchers from the B·ARGO group at the Germans Trias i Pujol Research Institute (IGTP) and from the Medical Oncology Department of the Catalan Institute of Oncology (ICO) in ...

BREAKWATER trial Cohort 3 analysis demonstrated statistically significant and clinically meaningful improvement in progression-free survival in BRAF V600E-mutant metastatic colorectal cancer Results ...